Ocular Therapeutix (OCUL) SEC Filings: History & Chart

Ocular Therapeutix, Inc.(OCUL)

Biotechnology · Bedford, MA

$7.48+0.23 (+3.18%)

Delayed quote: Oct 6, 2026, 2:55 PM EDT

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.

Bedford, MA

325 employees

www.ocutx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pravin U. Dugel

View full financials

Form	Filing Date	Accepted	Document
4	Sep 2, 2026	Sep 2, 2026	View filing
4	Aug 26, 2026	Aug 26, 2026	View filing
4	Aug 26, 2026	Aug 26, 2026	View filing
4	Aug 26, 2026	Aug 26, 2026	View filing
4	Aug 26, 2026	Aug 26, 2026	View filing
S-8	Aug 3, 2026	Aug 3, 2026	View filing
10-Q	Aug 3, 2026	Aug 3, 2026	View filing
8-K	Aug 3, 2026	Aug 3, 2026	View filing
SC 13G/A	Jul 29, 2026	Jul 29, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 12, 2026	Jun 12, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	May 28, 2026	May 28, 2026	View filing
4	May 28, 2026	May 28, 2026	View filing
4	May 28, 2026	May 28, 2026	View filing
4	May 28, 2026	May 28, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
10-Q	May 5, 2026	May 5, 2026	View filing
8-K	May 5, 2026	May 5, 2026	View filing
DEFA14A	Apr 30, 2026	Apr 30, 2026	View filing
DEF 14A	Apr 30, 2026	Apr 30, 2026	View filing
ARS	Apr 30, 2026	Apr 30, 2026	View filing
4	Apr 13, 2026	Apr 13, 2026	View filing

SEC Filings

Recent Filings